Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Glycomantra Inc
Profile last edited on: 1/12/2018      CAGE: 796D7      UEI: GJJRLDPAL8M9

Business Identifier: carbohydrate-based therapeutics for cancer and infectious diseases
Year Founded
2014
First Award
2016
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

24793 Shells Way
Aldie, VA 20105
   (410) 328-1396
   N/A
   www.glycomantra.com/
Location: Single
Congr. District: 10
County: Loudoun

Public Profile

Glycomantra Inc is a biotechnology firm in the translational glycobiology space developing carbohydrate-based therapeutics for cancer and infectious diseases. The company has developed natural high affinity galectin-3 inhibitors (patent pending) that may be used to treat cancers and fibrotic diseases. The company also offers Protein Purification & Assay Development and Consultation & Training.

Extent of SBIR involvement

User Avatar
Phase I Awards
6
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$1,721,888
Phase II Dollars
$40,000
Total Awarded
$1,761,888

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2023 2 NIH $2,110,483
Project Title: Targeting Galectin-3 to Overcome Insulin Resistance in Type 2 Diabetes
2023 2 NIH $596,637
Project Title: Targeting galectin-3 to intervene COVID-19
2018 1 NIH $298,490
Project Title: Targeting Galectin-3 for Treatment of NASH Mediated Fibrosis
2018 1 NIH $300,000
Project Title: Targeting Galectin-3 to Overcome Drug Resistance in Metastatic Prostate Cancer Therapy
2017 1 NIH $298,517
Project Title: GRIM19 for head and neck cancer therapy

Key People / Management

  Hafiz Ahmed

  Dhan V Kalvakolanu

Company News

There are no news available.